Antibodies

12 July 2011

AnaptysBio Selects Novel Anti-IL17 mAb with Best-in-Class Potential

11 July 2011

Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab (Lemtrada (*)) in Multiple Sclerosis

11 July 2011

Micromet Announces Solid Tumor BiTE Antibody Collaboration with Amgen

8 July 2011

Baxter and Halozyme Announce Top-Line Results of Phase III Study of HyQ in Patients with Primary Immunodeficiency

7 July 2011

Phase 3 Trial of ZALTRAP (aflibercept) in Advanced Prostate Cancer to Continue as Planned at Recommendation of Independent Data Monitoring Committee

6 July 2011

biOasis Announces Transcend Vector Results With a Therapeutic Antibody That Targets Metastatic Breast Cancer

6 July 2011

Amgen and UCB Team Up With NASA on Final Space Shuttle Mission to Conduct Preclinical Test of Sclerostin Antibody on Bone Loss

6 July 2011

Bristol-Myers Squibb and Innate Pharma Announce Breakthrough Global License Agreement for an Investigational Immuno-Oncology Biologic

30 June 2011

Ablynx Initiates a Phase I Study for Alx-0651, the First Nanobody in Clinical Development Targeting a Gpcr

30 June 2011

Roche provides update from FDA hearing on Avastin for metastatic breast cancer

29 June 2011

UCB to Launch Research Alliance With Harvard University

29 June 2011

EYLEA (aflibercept injection) Submitted in Japan for Marketing Authorization for the Treatment of Wet Age-Related Macular Degeneration

28 June 2011

The Lancet Publishes Data from Protege, MacroGenics’ Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients

28 June 2011

Two Pivotal Phase III Lucentis Studies Showed Patients With Diabetic Macular Edema Experienced Significant Improvements in Vision and Fewer Developed More Advanced Retinopathy

28 June 2011

Morphotek, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer

27 June 2011

Millennium Announces EMA Acceptance of Marketing Authorization Application for ADCETRIS (Brentuximab Vedotin)

27 June 2011

Amgen Submits Application to Expand Indication for XGEVA (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone

27 June 2011

XOMA Discovers Two New Classes of Insulin Receptor-Regulating Antibodies

24 June 2011

Amgen Receives Positive CHMP Opinion for Vectibix (Panitumumab) in Combination With Chemotherapy

24 June 2011

Genmab Announces Zalutumumab Update

24 June 2011

Baxter Receives Positive Opinion for IVIG Therapy in Europe for Treatment of Multifocal Motor Neuropathy

24 June 2011

iCo Therapeutics Executes Bertilimumab License with Immune Pharmaceuticals

22 June 2011

European Commission Approves Inclusion of Anti-JC Virus Antibody Status as a PML Risk Factor in TYSABRI Labeling

21 June 2011

Abbott and Biotest Announce Global Agreement to Develop and Commercialize Novel Antibody for Autoimmune Diseases

21 June 2011

Compugen Announces Initial Validation of Additional B7/CD28 Protein Family Based Product Candidate

20 June 2011

Alder Biopharmaceuticals to Receive $15 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2b Clinical Trial in Rheumatoid Arthritis of ALD518/BMS-945429 Antibody Therapeutic Against IL-6

20 June 2011

Alexion Initiates Clinical Trial of Eculizumab as a Potential Treatment for Patients with STEC-HUS in Expanded Response to EHEC Crisis in Germany

17 June 2011

Regeneron Announces EYLEA (aflibercept ophthalmic solution) Receives Unanimous Recommendation for Approval for Treatment of Wet AMD from FDA Advisory Committee

17 June 2011

Immune System Therapeutics Limited Drug Shows Positive Response in Patients with Multiple Myeloma Blood Cancer

16 June 2011

Phase II Study Evaluates Clinical Benefit of Combining REVLIMID with rituximab to Enhance Anti-Cancer Activity in Mantle Cell Lymphoma

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

c-Met-Targeted Antibody Therapy Pipeline Review

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

B7-H4 Targeted Antibody Therapy Pipeline Review